Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bendamustine Hydrochloride
/ administration & dosage
Drug Eruptions
/ genetics
Female
Follow-Up Studies
Humans
Interleukin-2
/ genetics
Lymphoma, Mantle-Cell
/ drug therapy
Male
Middle Aged
Neutropenia
/ chemically induced
Polymorphism, Single Nucleotide
Rituximab
/ administration & dosage
Non-Hodgkin lymphoma
bendamustine
outcome
rituximab
single nucleotide polymorphisms
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
27
05
2018
accepted:
24
07
2018
pubmed:
12
9
2018
medline:
19
9
2019
entrez:
12
9
2018
Statut:
ppublish
Résumé
Bendamustine is used in combination with rituximab (BR) to treat indolent non-Hodgkin lymphomas (iNHL) and mantle cell lymphoma (MCL). The variability in treatment efficacy and toxicity could be related to single nucleotide polymorphisms (SNPs) in immune response genes. We would like to show a correlation between SNPs and treatment outcome in iNHL and MCL patients receiving BR. We investigated some SNPs that had already been associated with NHL outcome. Samples were genotyped for the IL2 (rs2069762), IL10 (rs1800890, rs10494879), VEGFA (rs3025039), IL8 (rs4073), CFH (rs1065489) and MTHFR (rs1801131) SNPs by allelic discrimination assays. We enrolled 70 patients that received rituximab 375 mg/m
Substances chimiques
IL2 protein, human
0
Interleukin-2
0
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
223-231Informations de copyright
© 2018 British Society for Haematology and John Wiley & Sons Ltd.